Genelux Corporation (GNLX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GNLX
- Company Genelux Corporation
- Price $3.19
- Changes Percentage 20.38
- Change 0.54
- Day Low $2.66
- Day High $3.34
- Year High $20.62
- Year Low $1.6
- Market Cap $110,168,159
- Price Avg 50 EMA (D) $2.28
- Price Avg 200 EMA (D) $4.82
- Exchange NASDAQ
- Volume 360,481
- Average Volume 134,167
- Open $2.66
- Previous Close $2.65
- EPS -0.97
- PE -3.29
- Earnings Announcement 2024-11-12 12:00:00
- Shares Outstanding $34,535,473
Company brief: GENELUX CORPORATION (GNLX )
- Healthcare
- Biotechnology
- Mr. Thomas Zindrick J.D.
- https://www.genelux.com
- US
- N/A
- 01-26-2023
- US36870H1032
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.